NASDAQ:MCRB Seres Therapeutics (MCRB) Stock Price, News & Analysis $4.55 +0.07 (+1.56%) As of 03:27 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Seres Therapeutics Stock (NASDAQ:MCRB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Seres Therapeutics alerts:Sign Up Key Stats Today's Range$4.44▼$4.6750-Day Range$4.48▼$8.1452-Week Range$4.44▼$29.98Volume25,216 shsAverage Volume71,734 shsMarket Capitalization$45.23 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingHold Company Overview Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted. Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection. Seres is also advancing SER-287 in ulcerative colitis, SER-401 in combination with immunotherapy for certain cancers, and other preclinical programs targeting metabolic and inflammatory diseases. The company collaborates with strategic partners, including Nestlé Health Science, to support development, manufacturing scale-up and global research efforts. Founded in 2010, Seres went public in 2015 to further accelerate its clinical pipeline. The management team comprises experienced biotech executives, clinicians and scientists with expertise in microbiome research and product development. Seres continues to conduct multi‐center clinical trials across North America and Europe, seeking to bring first‐in‐class microbiome therapies to patients with limited treatment options.AI Generated. May Contain Errors. Read More Seres Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreMCRB MarketRank™: Seres Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 518th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingSeres Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSeres Therapeutics has a consensus price target of $17.00, representing about 274.4% upside from its current price of $4.54.Amount of Analyst CoverageSeres Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Seres Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Seres Therapeutics are expected to grow in the coming year, from ($4.36) to ($2.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seres Therapeutics is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seres Therapeutics is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeres Therapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.34% of the float of Seres Therapeutics has been sold short.Short Interest Ratio / Days to CoverSeres Therapeutics has a short interest ratio ("days to cover") of 5.92.Change versus previous monthShort interest in Seres Therapeutics has recently increased by 3.67%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSeres Therapeutics does not currently pay a dividend.Dividend GrowthSeres Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.36 News SentimentSeres Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Seres Therapeutics this week, compared to 2 articles on an average week.Search Interest3 people have searched for MCRB on MarketBeat in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Seres Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.20% of the stock of Seres Therapeutics is held by insiders.Percentage Held by Institutions59.34% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Seres Therapeutics' insider trading history. Receive MCRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MCRB Stock News HeadlinesHC Wainwright Analysts Decrease Earnings Estimates for MCRBAugust 9, 2026 | americanbankingnews.comSeres Therapeutics (NASDAQ:MCRB) Upgraded by Wall Street Zen to Hold RatingAugust 8, 2026 | americanbankingnews.comSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One under $5 company's High Altitude Head Start technology could bring that down to $20,000 per launch, or $2 million across 100 missions - a 10X cost advantage. It is already flying with paying customers, but shares may not stay this cheap once Wall Street notices.August 14 at 1:00 AM | Freedom Financial (Ad)Seres Therapeutics: Q2 Earnings SnapshotAugust 5, 2026 | finance.yahoo.comSeres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities CostsAugust 5, 2026 | finance.yahoo.comSeres Therapeutics Streamlines Cambridge Operations with Lease ChangesAugust 4, 2026 | tipranks.comSeres Therapeutics' SER-155 posts 80% response in cancer immunotherapy GI toxicity studyJuly 11, 2026 | msn.comSeres Therapeutics Shareholders Approve Directors and Executive PayJuly 8, 2026 | tipranks.comSee More Headlines MCRB Stock Analysis - Frequently Asked Questions How have MCRB shares performed this year? Seres Therapeutics' stock was trading at $14.88 on January 1st, 2026. Since then, MCRB stock has decreased by 69.5% and is now trading at $4.54. How were Seres Therapeutics' earnings last quarter? Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its quarterly earnings results on Wednesday, August, 5th. The biotechnology company reported $0.47 EPS for the quarter, topping analysts' consensus estimates of ($2.18) by $2.65. The biotechnology company earned $0.74 million during the quarter, compared to the consensus estimate of $0.18 million. Seres Therapeutics had a negative net margin of 1,192.94% and a negative trailing twelve-month return on equity of 114.82%. When did Seres Therapeutics' stock split? Seres Therapeutics's stock reverse split before market open on Tuesday, April 22nd 2025.The 1-20 reverse split was announced on Thursday, April 10th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Seres Therapeutics IPO? Seres Therapeutics (MCRB) raised $119 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 7,430,555 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. How do I buy shares of Seres Therapeutics? Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Seres Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Seres Therapeutics investors own include PayPal (PYPL), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Micron Technology (MU), Qualcomm (QCOM) and NIO (NIO). Company Calendar Last Earnings8/05/2026Today8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 MCRB's financial health is in the Red zone, according to TradeSmith. MCRB has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MCRB CIK1609809 Webwww.serestherapeutics.com Phone(617) 945-9626FaxN/AEmployees330Year Founded2010Price Target and Rating Average Price Target for Seres Therapeutics$17.00 High Price Target$22.00 Low Price Target$12.00 Potential Upside/Downside+276.9%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($2.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.70 million Net Margins-1,192.94% Pretax Margin-1,192.94% Return on Equity-114.82% Return on Assets-34.15% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual Sales$1.88 million Price / Sales23.81 Cash Flow$1.04 per share Price / Cash Flow4.34 Book Value$3.47 per share Price / Book1.30Miscellaneous Outstanding Shares9,941,000Free Float9,424,000Market Cap$44.83 million OptionableOptionable Beta0.20 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:MCRB) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredWhy November 27 Is Quickly Becoming America's Most Important Financial Date in DecadesAn estimated $10 trillion could move through a little known government initiative, according to analyst Joel L...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
